Market Cap
$247.2M
TRDA
Entrada Therapeutics, Inc.
$5.38 ▼ -5.28%
Prev close $5.68Market cap$247.2M
12-mo target$19.00 (+253.2%)
Insider Selling Cluster (2 insiders)21 New Institutional Positions8 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on TRDA right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Inst. Holders
50 funds
Inst. Value
$129.8M
Inst. Activity
21 buys / 8 sells
Insider Activity
$29.3K buy / $11.3M sell
Insider Net $
-$11.3M
SEC Reports
17
Press Releases
1
Price chart 30d -25.0%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 10, 2026 SEC Sep 3, 2026 SEC
Two MPM BioVentures funds (10% owners) sold a combined $547K in TRDA shares over two days, part of a larger 7-day cluste
CLUSTER — Impact 6/10
Sep 9, 2026 Insider
MPM BioVentures 2014, L.P. sold 28,837 shares
10%+ Owner @ $7.13 ($205.6K)
Sep 9, 2026 Insider
MPM BIOVENTURES 2018, L.P. sold 28,837 shares
10%+ Owner @ $7.13 ($205.6K)
Sep 8, 2026 Insider
Sep 4, 2026 SEC MPM BioVentures 2014, L.P. sold 192,500 shares
10%+ Owner @ $7.41 ($1.4M)
Two 10% owner entities (MPM BioVentures 2014 and 2018) sold a combined $515K in open-market shares over a week, represen
CLUSTER — Impact 3/10
Two 10% owner entities (MPM BioVentures 2014 and 2018) sold a combined 88.5K shares for ~$619K in open-market sales over
CLUSTER — Impact 4/10
Sep 2, 2026 other
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 30, 2026 Inst.
MILLENNIUM MANAGEMENT LLC — ADD
763,959 shares ($5.6M)
Analyst ratings buy % -5.5%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Jun 8, 2026 | Guggenheim | MAINTAIN | Buy | 52% |
| May 8, 2026 | HC Wainwright & Co. | DOWNGRADE | Neutral | 43% |
| Apr 6, 2026 | Oppenheimer | MAINTAIN | Outperform | 52% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% | |
| Aug 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% | |
| Jul 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% | |
| Jun 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% | |
| May 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 5 | 7 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 5 | 7 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% |
Price targets
Where 4 covering analysts think TRDA trades over the next 12 months.
$19.00 +253.2% upside Strong Buy
Current$5.38 Low$11.00 Median$20.00 High$25.00 4 analysts
$11.00$25.00
Analyst rating None as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
17 SEC filing reports analyzed · 0 bullish, 4 bearish, 1 mixed, 12 neutral · avg impact 3.8/10.Plus 1 press releases.
BEARISHCLUSTER6/10
Two MPM BioVentures funds (10% owners) sold a combined $547K in TRDA shares over two days, part of a
Sep 10, 2026
NEUTRALCLUSTER3/10
Two 10% owner entities (MPM BioVentures 2014 and 2018) sold a combined $515K in open-market shares o
Sep 4, 2026
NEUTRALCLUSTER4/10
Two 10% owner entities (MPM BioVentures 2014 and 2018) sold a combined 88.5K shares for ~$619K in op
Sep 3, 2026
NEUTRALCLUSTER4/10
Two 10% owner entities (MPM BioVentures 2014 and 2018) sold a combined ~$1.44M of TRDA shares over f
Sep 1, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 2, 2026
other
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 12, 2026
earnings_calendar
TRDA Q2 2026 Earnings Before Market Open — 2026-08-12
Aug 5, 2026
earnings
Entrada Therapeutics Reports Second Quarter 2026 Financial Results
Entrada Therapeutics reports financial results for the second quarter ended June 30, 2026, and highlights recent business updates.
Aug 4, 2026
earnings_calendar
TRDA Q2 2026 Earnings Before Market Open — 2026-08-04
Jun 2, 2026
fda
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
An independent safety Data Monitoring Committee recommends the initiation of Cohort 2 in Entrada Therapeutics’ ELEVATE-45-201 study.
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.99 | $-1.22–$-0.62 | 6.7% | -0.7% | 3↑ 3↓ | $0.0B | 7 |
| Next Q | $-0.88 | $-1.17–$-0.30 | 6.1% | +0.5% | 2↑ 3↓ | $0.0B | 7 |
| Current FY | $-3.79 | $-4.35–$-3.00 | -9.3% | -3.2% | 4↑ 2↓ | $0.0B | 7 |
| Next FY | $-3.01 | $-4.31–$-1.87 | 20.7% | +7.0% | 4↑ 1↓ | $0.0B | 6 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.989 | — |
| 7d ago | $-0.980 | -0.009 |
| 30d ago | $-0.981 | -0.007 |
| 60d ago | $-0.939 | -0.050 |
| 90d ago | $-0.939 | -0.050 |
Institutional ownership
Which big funds own TRDA (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $129.8M total value (17,588,475 shares) as of 2026-Q2. Top holders: BAKER, BlackRock,, VANGUARD. Net buying activity: 21 institutions added/increased vs 8 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 5,072,730 | $37.3M | 28.8% | — |
| BlackRock, Inc. | 2,583,333 | $19.0M | 14.6% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,269,634 | $9.3M | 7.2% | — |
| WELLINGTON MANAGEMENT GROUP LLP | 954,419 | $7.0M | 5.4% | — |
| MILLENNIUM MANAGEMENT LLC | 763,959 | $5.6M | 4.3% | ADD +47.1% |
| GEODE CAPITAL MANAGEMENT, LLC | 717,430 | $5.3M | 4.1% | — |
| AQR CAPITAL MANAGEMENT LLC | 699,537 | $5.1M | 4.0% | DOUBLED +202.8% |
| STATE STREET CORP | 596,677 | $4.4M | 3.4% | — |
| JPMORGAN CHASE & CO | 496,457 | $3.8M | 2.9% | DOUBLED +3243.8% |
| CITADEL ADVISORS LLC | 394,323 | $2.9M | 2.2% | ADD +83.4% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| MILLENNIUM MANAGEMENT LLC | ADD | 519,356 | 763,959 | +47.1% | $5.6M |
| JPMORGAN CHASE & CO | DOUBLED | 14,847 | 496,457 | +3243.8% | $3.8M |
| CITADEL ADVISORS LLC | ADD | 215,018 | 394,323 | +83.4% | $2.9M |
| NORTHERN TRUST CORP | ADD | 234,992 | 309,942 | +31.9% | $2.3M |
| Quantinno Capital Management LP | DOUBLED | 71,018 | 188,839 | +165.9% | $1.4M |
| Woodline Partners LP | TRIM | 215,977 | 145,600 | -32.6% | $1.1M |
| Trexquant Investment LP | ADD | 82,733 | 140,143 | +69.4% | $1.0M |
| BNP PARIBAS FINANCIAL MARKETS | TRIM | 181,148 | 95,044 | -47.5% | $699.5K |
| Allspring Global Investments Holdings, LLC | DOUBLED | 19,465 | 93,538 | +380.5% | $688.4K |
| ROYCE & ASSOCIATES LP | TRIM | 120,845 | 82,902 | -31.4% | $610.2K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
13 insiders, 50 transactions. Net -$11.3M — $29.3K bought, $11.3M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 9, 2026 | MPM BioVentures 2014, L.P. | 10%+ Owner | SELL | 28,837 | $7.13 | $205.6K |
| Sep 9, 2026 | MPM BIOVENTURES 2018, L.P. | 10%+ Owner | SELL | 28,837 | $7.13 | $205.6K |
| Sep 8, 2026 | MPM BioVentures 2014, L.P. | 10%+ Owner | SELL | 192,500 | $7.41 | $1.4M |
| Sep 8, 2026 | MPM BIOVENTURES 2018, L.P. | 10%+ Owner | SELL | 192,500 | $7.41 | $1.4M |
| Sep 4, 2026 | MPM BioVentures 2014, L.P. | 10%+ Owner | SELL | 38,500 | $7.11 | $273.7K |
| Sep 4, 2026 | MPM BIOVENTURES 2018, L.P. | 10%+ Owner | SELL | 38,500 | $7.11 | $273.7K |
| Sep 3, 2026 | MPM BIOVENTURES 2018, L.P. | 10%+ Owner | SELL | 32,263 | $7.17 | $231.3K |
| Sep 3, 2026 | MPM BioVentures 2014, L.P. | 10%+ Owner | SELL | 32,263 | $7.17 | $231.3K |
| Sep 2, 2026 | WENTWORTH KORY JAMES | Chief Financial Officer | TAX W/H | 1,733 | $7.14 | $12.4K |
| Sep 2, 2026 | Sethuraman Natarajan | President, Research & Develop. | TAX W/H | 2,079 | $7.14 | $14.9K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for TRDA.
Shares short
2,744,145
Settlement Sep 15, 2026
Change vs prior
+17.0%
Semi-monthly cycle
Days to cover
8.1
At avg daily volume
Of shares outstanding
≈7.0%
Estimate — not % of float
All TRDA filing & press-release reports (18)
- CLUSTER reportSep 10, 2026
- CLUSTER reportSep 4, 2026
- CLUSTER reportSep 3, 2026
- CLUSTER reportSep 1, 2026
- CLUSTER reportAug 31, 2026
- CLUSTER reportAug 27, 2026
- CLUSTER reportAug 11, 2026
- 8-K reportAug 5, 2026
- CLUSTER reportAug 4, 2026
- 144 reportJul 30, 2026
- 8-K reportJun 10, 2026
- PRESS-RELEASE reportJun 2, 2026
- PRESS-RELEASE reportMay 7, 2026
- CLUSTER reportMay 4, 2026
- 144 reportMay 4, 2026
- DEFA14A reportApr 24, 2026
- CLUSTER reportMar 11, 2026
- 8-K reportFeb 26, 2026